期刊文献+

高效液相色谱-质谱联用法测定人血浆中替格瑞洛及其代谢物的浓度 被引量:4

Simultaneous determination of ticagrelor and its active metabolitein in human plasma by HPLC-MS/MS
原文传递
导出
摘要 目的建立高效液相色谱-质谱联用法同时测定人血浆中替格瑞洛及其活性代谢产物AR-C124910XX的浓度。方法血浆样品用乙腈沉淀蛋白后,以伊曲康唑为内标,用Eclipse Plus-C_(18)色谱柱(2.1 mm×10 mm,3.5μm),以乙腈-10 mmol·L^(-1)醋酸铵溶液(均含0.15%甲酸)为流动相进行梯度洗脱,流速为0.3 mL·min^(-1),柱温为30℃,进样量10μL,总分析时间为4 min,用电喷雾离子化源,正离子方式,多反应监测(MRM)扫描方式进行监测。考察其专属性、标准曲线与定量下限、精密度与准确度、提取回收率、基质效应和稳定性。结果血浆中替格瑞洛的标准曲线方程为:y=3.79×10^(-2)x+5.27×10^(-3)(r=0.997 6),线性范围为2~2000μg·L^(-1),线性相关良好,定量下限为2μg·L^(-1);AR-C124910XX标准曲线方程为:y=4.58×10^(-2)x+6.15×10^(-3)(r=0.996 5),线性范围为1~1000μg·L^(-1),线性相关良好,定量下限为1μg·L^(-1)。替格瑞洛和AR-C124910XX低、中、高3个质量浓度的准确度在93.6%~108.7%;日内、日间的相对标准偏差(RSD)均小于15%;提取回收率在84.7%~91.3%。结论液质联用法快速、灵敏、准确,专属性强,重复性好,适用于人血浆中替格瑞洛及其活性代谢产物AR-C124910XX的浓度测定。 Objective To establish an HPLC- MS / MS method for simultaneous determination of ticagrelor and its active metabolite( AR-C124910XX) in human plasma. Methods The plasma samples were precipitated protein by acetonitrile,with itraconazoleas an internal standard. The separation was achieved on Eclipse Plus- C(18)column( 2. 1 mm× 10 mm,3. 5 μm) and eluted with linear gradient by mobile phase consisted of acetonitrile and 10 mmol·L^-1ammonium acetate,both of which were acidified with 0. 15% formicacid,at the flow rate of 0. 3mL ·min^-1. The injection volume was 10 μL and the column temperature was 30 ℃. The total time of the analysis was 4. 0 minutes. Detection of the analytes were achieved using positive ion electrospray ionization( ESI) in the multiple reaction monitoring( MRM) mode. The specificity,standard curve and lower limit of quantitation,precision and accuracy,extraction recoveries,the matrix effect and stability were investigated.Results The linear range of ticagrelor was 2- 2000 μg · L^-1. The linear regression equation was y = 3. 79 × 10^-2x + 5. 27 × 10^-3( r =0. 997 6)with the lower limit of quantitation( LLOQ) of 2 μg·L^-1. While liner range of AR- C124910 XX was 1- 1000 μg·L^-1( r =0. 996 5),and the standard curve was y =4. 58 ×10^-2x + 6. 15 × 10^-3( r =0. 996 5) with LLOQ of 1 μg·L^-1. The accuracy of low,medium and high concentrations of ticagrelor and AR- C124910 XX was 93. 6%- 108. 7%. The intra- day and inter- day relative standard deviations( RSD) were both less than 15%. The extraction recoveries were84. 7%- 91. 3%. Conclusion The established method is rapid,sensitive,accurate,specific and reliable,and suitable for simultaneous determination of ticagrelor and its active metabolite( AR- C124910XX) in human plasma.
机构地区 浙江医院药剂科
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第13期1223-1226,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家科技重大专项基金资助项目(2013ZX09303005) 浙江省自然科学基金资助项目(LQ15H310003)
关键词 替格瑞洛 代谢产物 液质联用法 血药浓度 ticagrelor metabolite HPLC-MS/MS plasma concentration
  • 相关文献

参考文献7

  • 1MARCZEWSKI M M, POSTULA M, KOSIOR D. Novel antiplatelet agents in the prevention of cardiovascular complications - focus on ti- cagrelor[ J/OL ]. 2010 - 05 - 24 [ 2015 - 09 - 27 ]. http ://www. nebi. nlm. nih. gov/pmc/artieles/PMC2882894/pdf/vhrm- 6- 419. pdf.
  • 2章霞,柯永胜.新型P2Y12受体抑制剂替格瑞洛临床研究进展[J].中国临床药理学与治疗学,2014,19(4):459-464. 被引量:22
  • 3TENG R, OLIVER S, HAYES M A,et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects[ J]. Drug Metab Dispos, 2010,38(9) :1514 -1521.
  • 4ZHOU D, ANDERSSON T B, GRIMM S W. In vitro evaluation of potential drug - drug interactions with ticagrelor: cytochrome 17450 reaction phenotyping, inhibition, induction, and differential kinetics [J]. Drug Metab D/spos,2010, 39(4) :703 -710.
  • 5SILLIN H, COOK M, DAVIS P. Determination of unbound ti- cagrelor and its active metabolite (AR- C124910XX) in human plasma by equilibrium dialysis and LC -MS/MS[ J]. J Chromatogr B,2011,879(23) :2315 -2322.
  • 6JEON H S, KIM M J, CHOI H Y, et al. Pharmaeokineties and phar- maeodynamics of ticagrelor and prasugrel in healthy male Korean volunteers [J]. Clin Ther,2015, 37(3): 563-573.
  • 7TENG R, BUTLER K. Safety, tolerability, pharmacokinetics and pharmacodynamics of high single - ascending doses of ticagrelor in healthy volunteers[J]. Int J Clin Pharmacol Ther,2013,51 (10) : 795 - 806.

二级参考文献31

  • 1World Health Organization. Top ten causes of death. Geneva.. World Health Organization 2011. Available from : http ://www. who. int/ me- diacentre/factsheets/fs310. 2008. pdf. Accessed December 14,2012.
  • 2Behan MW, Chew DP, Aylward PE. The role of antiplatelet therapy in the secondary prevention of coronary artery disease[J]. Curr Opin Cardiol, 2010, 25(4): 321-328.
  • 3Marczewski MM, Postula M, Kosior D. Novel an tiplatelet agents in the prevention of cardiovascular complications- focus on ticagrelor [J].Vase Health Risk Manag, 2010, 6:419-429.
  • 4Siller-Matula JM, Krumphuber J, Jilma B. Phar- macokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disea- ses[J]. BrJ Pharmacol, 2010, 159(3): 502-517.
  • 5Zhou D, Andersson TB, Grimm SW. In vitro eval- uation of potential drug-drug interactions with ti- cagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics[J]. Drug Metab Dispos, 2011, 39(4): 703-710.
  • 6Teng R, Oliver S, Hayes MA. Absorption, distri- bution, metabolism: and excretion of ticagrelor in healthy subjects[J]. Drug Metab Dispos, 2010, 38(9) : 1514-1521.
  • 7Teng R, Butler K. Pharmacokinetics,pharmacody- namics, tolerability and safety of single ascending doses of ticagrelor,a reversibly binding oral P2Y12 receptor antagonist in healthy subjects[J]. Eur J Clin Pharmacol, 2010, 66(5): 487-496.
  • 8Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and re- sponders and effect of switching therapies:the RE- SPOND study[J]. Circulation, 2010, 121 (10): 1188-1199.
  • 9Husted S, Emanuelsson H, Hepinstall S, et ai. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin [J]. Eur Heart J, 2006, 27(9): 1038-1047.
  • 10Gurbel PA, Bliden KP, Butler K, et al. Random- ized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor ver- sus clopidogrel in patients with stable coronary dis ease: the ONSET/OFFSET study[J]. Circulation, 2009, 120(25): 2577-2585.

共引文献21

同被引文献33

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部